Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million

Consortium led by eTheRNA immunotherapies…

ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases

ConserV Bioscience and eTheRNA immunotherapies…

eTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focussed on eTheRNA’s proprietary mRNA development products and manufacturing capabilities

eTheRNA and China Grand Pharma…

eTheRNA extends senior management team with appointment of Michael Mulqueen as VP Business Development

eTheRNA extends senior management team…

eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through toclinical proof of concept

eTheRNA raises EUR 34 million…

eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations

eTheRNA launches an international consortium…

Safety and immune stimulation data from an intranodal delivery of TriMix mRNA

Safety and immune stimulation data…

Appointment of Chief Financial Officer

Niel (Belgium), 29 May 2019…